Basilea wins USD 30 million BARDA funding for phase 3 antifungal fosmanogepix

• Basilea won USD 30 million in additional BARDA funding to support its phase 3 program for antifungal fosmanogepix.
• Funding was triggered by reaching a prespecified enrollment milestone under an existing OTA signed in September 2024.
• Total BARDA commitments under the agreement rise to USD 123 million, with potential non-dilutive funding up to about USD 268 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607290115OMX_____CNEWS_EN_GNW1001254880_en) on July 29, 2026, and is solely responsible for the information contained therein.